<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01061450</url>
  </required_header>
  <id_info>
    <org_study_id>Statin_DD</org_study_id>
    <nct_id>NCT01061450</nct_id>
  </id_info>
  <brief_title>Simvastatin and Diastolic Dysfunction</brief_title>
  <official_title>Effect of the Addition of Simvastatin to Enalapril in Hypertensive Individuals With Average Cholesterol Levels and Diastolic Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brasilia Heart Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundação de Amparo a Pesquisa do Distrito Federal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Brasilia Heart Study Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diastolic dysfunction (DD) is an increasingly frequent condition in hypertensive individuals
      whose treatment remains unclear. Its presence is related to higher morbidity and mortality
      independent of blood pressure levels. The aim of this study is to investigate the additive
      effect of simvastatin on enalapril on DD in hypertensive patients with average cholesterol
      levels.

      For this aim, hypertensive patients with DD and LDL-cholesterol &lt;160 mg/dL will undergo a
      run-in phase to achieve a systolic blood pressure (SBP) &lt;135 mmHg and diastolic blood
      pressure (DBP) &lt;85 mmHg with enalapril. Hydrochlorothiazide could be added when need to
      achieve SBP or DBP control. Four weeks after reaching the optimum anti-hypertensive regimen
      patients will be randomized to receive 80 mg simvastatin or placebo for a period of 20 weeks.
      Echocardiograms will be performed before and after treatment with measurement of left atrial
      volume, conventional and tissue Doppler velocities in early diastole and late diastole. The
      evaluation of these will allow to identify changes of DD severity after treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in E/A ratio and e' wave velocity</measure>
    <time_frame>20 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in left atrium volume.</measure>
    <time_frame>20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in left ventricular mass.</measure>
    <time_frame>20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in e´/a´ waves ratio.</measure>
    <time_frame>20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in mitral deceleration time.</measure>
    <time_frame>20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the ratio of mitral inflow velocity to annular relaxation velocity.</measure>
    <time_frame>20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in mitral annulus systolic velocity</measure>
    <time_frame>20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic function reserve index measured at peak stress with dobutamine</measure>
    <time_frame>20 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Diastolic Dysfunction</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Simvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Simvastatin 80 mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>80 mg once a day</description>
    <arm_group_label>Simvastatin</arm_group_label>
    <other_name>Zocor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 pill once a day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  men or postmenopausal women aged between 40 and 65 years old

          -  normal fasting blood glucose (&lt;100 mg/dL) and glucose tolerance test (&lt;140 mg/dL)

          -  waist circumference &lt; 102 cm (men) or &lt; 88cm (women)

          -  triglycerides &lt;150 mg/dL, LDL cholesterol ≤ 160 mg/dl

          -  creatinine &lt;1.2 mg/dL, sinus rhythm

          -  the presence of grade 1 or 2 of DD with an ejection fraction of left ventricle &gt; 55%

          -  absence of myocardial ischemia during dobutamine stress echocardiography

        Exclusion Criteria:

          -  thyroid dysfunction

          -  acute or chronic liver disease

          -  regular use of 3 or more antihypertensive drugs

          -  secondary hypertension

          -  symptoms or history of atherosclerotic disease

          -  valvular dysfunction

          -  LVH 14 and use of statins in the last 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adenalva LS Beck, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>InCor Heart Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrei C Sposito, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Brasilia Medical School, Brasilia, Brazil</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria E Otto, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto de Cardiologia do Distrito Federal, Brasilia, Brazil</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto de Cardiologia do Distrito Federal</name>
      <address>
        <city>Brasilia</city>
        <state>DF</state>
        <zip>70000.000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2010</study_first_submitted>
  <study_first_submitted_qc>February 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2010</study_first_posted>
  <last_update_submitted>February 2, 2010</last_update_submitted>
  <last_update_submitted_qc>February 2, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2010</last_update_posted>
  <responsible_party>
    <name_title>Andrei C Sposito</name_title>
    <organization>Heart Institute (InCor), University of São Paulo Medical School, São Paulo, Brazil</organization>
  </responsible_party>
  <keyword>Diastolic dysfunction</keyword>
  <keyword>hypertension</keyword>
  <keyword>Statins</keyword>
  <keyword>ACE inhibitor</keyword>
  <keyword>Echocardiography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

